Contest2021-北15-新辅助免疫化疗后胸腹腔镜联合食管癌根治术
Minimally invasive esophagectomy after neoadjuvant immunochemotherapy Authors: Yinliang Sheng M.D, Yu Qi Ph.D, Chunyang Zhang Ph.D, Ping Yuan Ph.D,Bin Wu M.D The First Affiliated Hospital of Zhengzhou university Corresponding Author:Yinliang Sheng,1024223908@qq.com,15093145318 Abstract:The application of neoadjuvant immunotherapy and chemotherapy in locally advanced esophageal cancer is feasible, and it can achieve a good preoperative down-stage effect and reduce the risk of palliative and unresectable tumors. After neoadjuvant immunization and chemotherapy, local tissue edema, fibrosis and adhesion of the tissue structure after esophageal tumor regression are acceptable. Modular dissection of lymph nodes is also feasible, the exposure of the surgical field is clear, and the difficulty of the operation is controllable. After neoadjuvant immunotherapy, some patients have obvious vascular proliferation and tortuous. For thicker vessels, it is recommended to perform coagulation and disconnection after vascular clamping to reduce the risk of bleeding in the surgical field and delayed postoperative bleeding. Single-lumen endotracheal intubation should not exceed the level of the left inferior thyroid artery. If it is too deep, it will affect the exposure of the lymph nodes next to the left recurrent laryngeal nerve. The dissection of the lymph nodes adjacent to the left recurrent laryngeal nerve can be done by lightly suspending the esophagus on the dorsal side to perform segmental and bidirectional exposure modular dissection. Mild traction of the nerve does not increase the risk of left recurrent laryngeal nerve injury. Conflict of interests: None.
- Category: Esophageal surgery,Contest 2021
- Duration: 12:00
- Date: 3 years ago
- Tags: no-tag
18 Comments